BMJ Open

Functional decline and associated factors in patients with multimorbidity at 8 months of follow-up in primary care: the functionality in pluripathological patients (FUNCIPLUR) longitudinal descriptive study

Iñaki Martín Lesende,1 Luis Ignacio Mendibil Crespo,2 Sonia Castaño Manzanares,3 Anne-Sophie Denise Otter,3 Irati Garaizar Bilbao,4 Jakobe Pisón Rodríguez,3 Ion Negrete Pérez,5 Iraide Sarduy Azcoaga,6 María Jesús de la Rua Fernández7

ABSTRACT

Objective To analyse short-term functional decline and associated factors in over 65-year-olds with multimorbidity.

Design and setting Prospective multicentre study conducted in three primary care centres, over an 8-month period. During this period, we also analysed admissions to two referral hospitals.

Participants Of the 241 patients ≥65 years included randomly in the study, 155 were already part of a multimorbidity programme (stratified by ‘Adjusted Clinical Groups’) and 86 were newly included (patients who met Ollero’s criteria and with ≥1 hospital admission the previous year). Patients who were institutionalised, unable to complete follow-up or receiving dialysis were excluded.

Outcomes and variables The primary outcome was the decrease in functional status category (Barthel Index or Lawton Scale). Other variables considered were sociodemographic characteristics, comorbidity, medications, number of admissions and functional status on discharge.

Results Patients had a median age of 82 years (P75 86) and of five selected chronic conditions (IQR 4–6), and took 11 (IQR 9–14) regular medications; 46.9% were women; 38.2% had impaired function at baseline. Overall, 200 persons completed the follow-up; 10.4% (n=25) of the initial sample died within the 8 months. In 20.5% (95% CI 15.5% to 26.6%) of them we recorded a decrease in functionality, associated with older age (OR 1.1, 95% CI 1.0 to 1.2) and with having ≥1 admission during the follow-up (OR 3.6, 95% CI 1.6 to 7.7). There were 133 hospital admissions in total during the follow-up considering all the patients included, and a functional decline was observed in 35.5% (95% CI 25.7% to 46.7%) of the 76 discharges in which functional status was assessed.

Conclusions A fifth of patients showed functional decline or loss of independence in just 8 months. These findings are important as functional decline and the increasing care needs are potentially predictable and modifiable. Age and hospitalisation were closely associated with this decline.

Strengths and limitations of this study

- It is one of the few primary care studies which has been carried out in patients included in a clinical care multimorbidity programme, and focuses on functional decline as the main outcome variable.
- Two validated and widely used scales, in both basic (Barthel Index) and instrumental (Lawton Scale) activities of daily living (ADL), are used to assess functional status as the primary outcome variable.
- The 8 months of follow-up period is a relatively short time frame, however it is important in that it allows us to identify recent functional decline and facilitate early interventions.
- The fact that the assessment of the ADL was evaluated using a questionnaire and not directly assessed (ie, performance testing), coupled with the fact that data regarding ADL status on discharge were lacking in many patients after hospitalisation, could give a less precise picture of patients’ true functional status after discharge and in general.

INTRODUCTION

Considering the most common characteristics of patients with multimorbidity in specific management and care programmes and criteria for their inclusion, there are four that best define this subgroup of patients1 2: (A) advanced age; (B) the combination of two or more chronic health problems that can be considered ‘major’ (considering their impact at the personal level and quality of life, their clinical course and the associated need for care, or their effect on functional status), such as cardiovascular, lung, musculoskeletal and neurological diseases, diabetes, and so on3; (C) a high use of social and healthcare

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Dr Iñaki Martín Lesende; INAKI.MARTINLESENDE@osakidetza.eus

Check for updates

Received 14 February 2018
Revised 18 May 2018
Accepted 11 June 2018

To cite: Martín Lesende I, Mendibil Crespo L, Castaño Manzanares S, et al. Functional decline and associated factors in patients with multimorbidity at 8 months of follow-up in primary care: the functionality in pluripathological patients (FUNCIPLUR) longitudinal descriptive study. BMJ Open 2018;8:e022377. doi:10.1136/bmjopen-2018-022377

Open access
Research
resources, especially in relation to hospitalisation and contact with healthcare professionals; and (D) a high rate of some degree of established functional decline.\footnote{14,18}

Although these patients do not represent a high percentage of the population, they have a significant impact on health and social care resource use. In this context, one of the priorities of many healthcare organisations is to manage patients with multimorbidity in a structured manner to achieve a more effective and efficient delivery of care, within the overall care provided to chronic patients. From an operational perspective, several methods have been used for including patients in specific programmes.\footnote{19} It is common to carry out population stratification using strategies such as the Adjusted Clinical Groups (ACG), which categorises future healthcare needs based on the level of complexity and comorbidity of the people (http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?printer=Y&conceptID=1304); while elsewhere in Spain specific clinical criteria are also used such as that described by Ollero (Ollero’s criteria),\footnote{20} based on the coexistence of specific chronic diseases (cardiovascular, lung, neurological, musculoskeletal, kidney, digestive, autoimmune, diabetes, chronic anaemia and untreatable neoplasia).

Given the close association between multimorbidity and functional decline,\footnote{19} it seems necessary to identify and explore factors that may be related to or may modify this deterioration and its progression. Hence, as the best overall indicator of health status in elderly patients in general and those with multimorbidity in particular, functional status should be a priority in the goals and strategies of interventions focused on managing patients with multimorbidity, as such an approach might have a greater impact on outcomes\footnote{20} than focusing on the treatment of the comorbid conditions.\footnote{21} The International Classification of Functioning, Disability and Health (ICF) by the WHO, http://www.who.int/classifications/icf/en/, is the reference framework employed when measuring health and disability at an individual and population level, structured around several components: body functions and structure, activities of daily living (ADL) in terms of basic tasks and interactions with the immediate environment (basic activities of daily living, BADL), and more complex tasks and interactions within the community (instrumental activities of daily living, IADL), participation and environmental factors; it is difficult to consider the ICF as a practical instrument in daily clinical practice for measuring functional status, although most evaluation scales have similar components. Some of these instruments are BADL (eg, Barthel) and IADL (eg, Lawton) scales, short physical performance tests (generally assessing mobility, gait and balance), others self-completed or completed by caregivers or those based on the direct performance of activities, and so on.

Functional decline is associated with a higher probability of experiencing health-related adverse events with poorer outcomes, as well as increasing progression towards developing greater disability and loss of independence. Related factors associated with functional decline in patients with multimorbidity include: the number of concomitant chronic conditions,\footnote{8} the level of pre-existing disability,\footnote{8,10}11 and the history of hospitalisation.\footnote{22,23}

Addressing functional decline and associated factors is very transcendent in a progressively older population, especially in more vulnerable groups such as patients with multimorbidity. However, there are few studies that focus on patients with multimorbidity already included in clinical programmes who are receiving specific interventions and management, in the community setting, in primary care.

The objectives of this study were (A) to assess functional decline over an 8-month follow-up period in patients aged 65 years or more included in a clinical care programme for patients with multimorbidity; and (B) to investigate factors which may have an impact on this decline.

MATERIALS AND METHODS

Type of study and setting

A multicentre descriptive longitudinal prospective study, with analysis after 8 months of individual follow-up (within a global period from May 2016 to April 2017), was conducted in primary care, and included admissions to two referral hospitals (secondary care). This is part of a larger study investigating other variables related to multimorbidity and with longer follow-up periods.

We included patients from three urban primary care health centres in the Bilbao-Basurto Integrated Healthcare Organisation (IHO); one of them, San Ignacio Health Centre, has a solid research line in the elderly and the other two centres wanted to join in this specific research after asking for collaboration. As well as 23 primary care health centres, this IHO includes a main referral hospital (Basurto University Hospital), which has a unit for patients with multimorbidity within the Internal Medicine Department, and patients may also be referred to a subacute hospital (Santa Marina Hospital), which mainly cares for patients with multimorbidity or at the end of life. The study health centres had similar percentages of users ≥65 years of age to the mean in the IHO (23.5%), with 15, 17 and 14 general practitioner lists in each centre, and a similar number of nurses.

Figure 1 summarises the design and phases of the study.

Patients and sample

The study population was composed of patients ≥65 years old included in the local clinical care programme for patients with multimorbidity. The selection of patients (sample population) was carried out in two ways:

a. Taking the initial list of patients already included in the programme, via the patient stratification system used by the Basque Health Service (2013 data), based on ACGs and selecting approximately the top 5% of the ‘Kaiser Permanente pyramid’ (www.kaiserpermanente.org) (excluding palliative care patients or patients...
with limited life expectancy), and therefore including patients with certain diseases (chronic obstructive pulmonary disease, heart failure or diabetes mellitus) and at least one hospital admission.

b. During an initial period of 2 months, before the beginning of the selection of the sample and baseline assessments, we included in the study and programme new patients from the participating centres who met Ollero’s criteria and who had had at least one hospital admission in the previous year. These patients were included by the general practitioners or internal medicine specialists. Patients from a preliminary list based on the 2016 stratification were also included. The definition described by Ollero requires patients to have at least two different categories of certain relevant chronic conditions (cardiovascular, lung, neurological, musculoskeletal, kidney, digestive, autoimmune, diabetes, chronic anaemia and untreatable neoplasia). We excluded patients who were institutionalised, had limited life expectancy, or on dialysis, as well as those who we could not contact or were not able to complete the 8-month follow-up (eg, due to moving away or between the homes of different family members), had received a transplant, had active cancer, declined to participate or were considered unsuitable by their primary care doctor (for various reasons).

**Sample size**
To estimate the percentage of patients with multimorbidity whose functional status would change, we first calculated the number we needed to study based on the patients with multimorbidity registered in the Bilbao-Basurto IHO

---

**Figure 1** Design and phases of the study.
(n=1977). For a margin of error of ±6% with a 95% confidence level and an expected percentage of up to 30%, 201 individuals would have been needed, and allowing for losses to follow-up of 20% (based on preliminary studies), this increased to 241 patients.

From an initial set of 420 persons, we selected patients by simple random sampling, using the statistical software, obtaining a new list ordered according to this randomisation. After this, patients were progressively contacted and included or excluded until we reached a sample size of 241; 155 were already in the programme for patients with multimorbidity and 86 patients were newly added. The reasons for the 142 exclusions from the study are shown in figure 1; the ‘other’ criterion included errors in the listing (12, 8.5%), considered unsuitable by their primary care doctor (9, 6.3%), death (3, 2.1%) and institutionalisation (2, 1.5%).

On recruitment, all patients received a patient information sheet and signed the informed consent form. To ensure the confidentiality of patient data in the data collection sheet and database, individual identification codes were used.

**Study variables**

The primary outcome variable was the change in the patient’s functional status from baseline, 8 months after the initial assessment. To measure this we used the Barthel Index (assessing BADL) and the Lawton Instrumental Activities of Daily Living Scale (Lawton IADL Scale). We defined baseline functional status as the function of the patient when they were without exacerbations of their chronic health problems or had not had any hospital admissions in the previous 2 months.

These two scales are widely used and have been validated in our setting. The Barthel Index\(^{14}\) assesses 10 basic activities and the score, ranging from 0 to 100, can be interpreted using the following categories: independent (100), mildly dependent (60–95), moderately dependent (40–55), severely dependent (20–35) and totally dependent (<20). The Lawton Scale\(^{15}\) assesses more complex tasks (using the phone, shopping, using transportation, taking responsibility for one’s own medication, handling finances, preparing food, housekeeping and doing the laundry); we have used the version that assesses only five activities or had not had any hospital admissions in the previous 2 months.

In most cases, the general practitioners themselves initially contacted patients by phone to explain the study and invited the patients and their relatives to participate. In the initial assessment, at the health centre or in the patient’s home if required, the study was explained to patients in more detail, a patient information sheet was given to the patient and written informed consent was requested. For those included in the study, we took baseline measurements, and in addition to setting an alert in the electronic health record regarding the participation in the study, we gave them the names of hospital liaison nurse they or their relatives should contact in the event that they were admitted to hospital, and a mobile phone number to contact the research team in the case of such an event and difficulties to contact with the liaison nurse. If a patient was excluded, we recorded the reason behind this.

If patients were hospitalised, their functional status was assessed using the Barthel Index and the Lawton Scale at discharge by a hospital liaison nurse or in the 5 days following discharge by the primary care specialised nurse case manager or a research team member. At the end of the follow-up period, the evaluation scales (Barthel and Lawton) were used again in the same
conditions as those required for measuring baseline status (described above). Both baseline and the 8-month follow-up assessments were carried out by the researchers, general practitioners or by two trained collaborator physicians, in the health centre or in the patient’s home if required.

Patients and public involvement
Patients did not participate in the design and conception of this study; however, they had an active participation in certain aspects of their own clinical follow-up, that is, when they had an admission, contacting the hospital-specific nurses indicated on the patient information sheet or calling the telephone number provided by the researchers in case there was difficulty to contact and it was they who facilitate it. It was not planned to specifically disclose the results of the study to patients, beyond the institutional diffusion that this type of health programmes has in the media; although in the successive evaluations they were informed in a non-standardised way of the development of the project.

Analysis
Univariate analysis of baseline characteristics was performed using measures of central tendency and dispersion for quantitative variables and percentages for qualitative variables. Population values were estimated, through inferential statistical techniques, for the most relevant values. Bivariate analysis was performed to assess the association of functional status with the other variables, using Student’s t-test or the Mann-Whitney U test for quantitative variables (for data that were not normally distributed and for ordinal variables) and the χ² test for qualitative variables (according to whether or not functional status was treated as a quantitative, discrete or qualitative variable).

Multivariate analysis (binary logistical regression) was performed, by the ‘enter’ method, regarding functional decline (yes/no at the end of the follow-up) as the dependent variable and the following as independent variables: age, sex, baseline functional status, number of comorbid conditions, Charlson index, number of medications taken and hospital admissions during the follow-up period.

In addition, the ability of the baseline characteristics considered and having at least one hospital admission to discriminate between patients who did and who did not have functional decline at 8 months of follow-up was assessed with the C statistic (equivalent to the area under the curve). For this, values of 0.5 to <0.7, 0.7–0.9 and >0.9 were considered indicative of poor, good and excellent discrimination.17

A descriptive analysis of the losses to follow-up and their causes was done too, and imputation of the missing values of the sample was not applied.

All analyses were performed using the statistical software IBM-SPSS V.23, and with a statistical significance level of 0.05.

RESULTS
Initially, we included and assessed 241 patients. Subsequently, 41 (17%) were lost to follow-up, 25 due to death, 9 due to withdrawal from study, 3 due to institutionalisation and 4 due to patients having moved away or failure to contact them. There were no missing values in the baseline or final variables, except in the functional assessment at hospital discharge.

The 46.9% (n=113) of the study population were women. The median age was 82 years old (P75 86 years) which was significantly higher in women (median 83 and P75 88 years) than in men (median 80 and P75 84.7 years) (P=0.001).

Table 1 presents the distribution of the selected chronic conditions in the study population, overall and by sex. Included patients had a median of 5 of these conditions concurrently (IQR 4–6). The median in Charlson Index was 3 (IQR 2–4).

The median number of regular medications was 11 (IQR 9–14). By type, a median of 10 (IQR 8–12) were medications for ongoing chronic use, with a minimum of 4 and maximum of 24, and 1 (IQR 0–2) was for ‘as needed’ use. Women took more medications than men, in terms of both regular medications overall and those for chronic use: 12 (IQR 9–16) and 11 (IQR 8–13) vs 10 (IQR 9–13) and 9 (IQR 7–11), respectively, p=0.001 and 0.003.

Patients had a median of 1 (IQR 0–1) hospital admission in the year before the initial assessment, with 44.4% of the study population not being admitted in that period.

At baseline, 58.2% (95% CI 32.3 to 44.4) of patients (n=92) were classified as having impaired functional status, due to having scored <60 in the Barthel Index or moderate, severe or total functional impairment based on the Lawton Scale. Among this group, the level of functional impairment was the same for BADLs and IADLs in 32 patients, while the other 60 showed impaired IADL performance. As can be observed in table 2, women had poorer baseline functional status than men in terms of both BADL (Barthel Index) and IADL (Lawton Scale) performance.

In the logistic regression performed to analyse the association of impaired functional status at baseline with age, sex, the number of selected comorbid conditions, the total number of regular medications and the number of hospital admissions in the previous year, the model explaining between 21.4% and 29.1% of the variance in the dependent variable. The following variables reached significance: number of previous hospital admissions (OR=1.39, 95% CI 1.04 to 1.86, p=0.027), number of selected comorbid conditions (OR=1.36, 95% CI 1.08 to 1.71, p=0.009) and age (OR=1.13, 95% CI 1.07 to 1.19, p<0.001).

Comparing baseline variables between patients who had already been included or were newly included in the programme, the only significant differences detected were in the number of hospital admissions in the previous year (p=0.027), and among the chronic diseases considered in the prevalence of coronary
heart disease (48.4% in patients already included vs 32.6% in those newly included, p=0.017). There were no significant differences regarding the other variables (sex, age, number of medications, Barthel, Lawton, overall basal functional impairment or remaining comorbidity).

A total of 200 patients completed the follow-up. Of these, 41 (20.5%, 95% CI 15.5% to 26.6%) experienced functional decline from baseline; that is, they were classed in a lower category by the Barthel Index or Lawton Scale at follow-up in comparison to their baseline score. In this group, approximately half did and half did not have

Table 1  Distribution of the selected chronic conditions in the study population overall and stratified by sex

| Conditions considered                  | Total n=241 | Women n=113 | Men n=128 | P values* |
|----------------------------------------|------------|-------------|-----------|-----------|
| Hypertension, n (%)                    | 201 (83.4) | 98 (86.7)   | 103 (80.5) | 0.193     |
| Diabetes, n (%)                        | 143 (59.3) | 62 (54.9)   | 81 (63.3)  | 0.118     |
| Coronary heart disease, n (%)          | 103 (42.7) | 42 (37.2)   | 61 (47.7)  | 0.100     |
| Heart failure, n (%)                   | 110 (45.6) | 61 (54)     | 49 (38.3)  | 0.015     |
| Heart arrhythmia, n (%)                | 109 (45.2) | 52 (46)     | 57 (44.5)  | 0.817     |
| Stroke/cerebrovascular accident, n (%) | 60 (24.9)  | 25 (22.1)   | 35 (27.3)  | 0.350     |
| Symptomatic musculoskeletal diseases, n (%) | 118 (49)  | 71 (62.8)   | 47 (36.7)  | <0.001    |
| Chronic obstructive pulmonary disease/asthma, n (%) | 116 (48.1) | 50 (44.2)   | 66 (51.6)  | 0.257     |
| Substantial visual or hearing impairment, even with correction, n (%) | 61 (25.3)  | 34 (30.1)   | 27 (21.1)  | 0.109     |
| Chronic kidney disease, n (%)          | 60 (24.9)  | 25 (22.1)   | 35 (27.3)  | 0.350     |
| Chronic anaemia, n (%)                 | 50 (20.7)  | 22 (19.5)   | 28 (21.9)  | 0.646     |
| Mental illness (psychosis, depression, severe anxiety), n (%) | 30 (12.4)  | 21 (18.6)   | 9 (7)      | 0.007     |
| Dementia, n (%)                        | 26 (10.8)  | 10 (8.8)    | 16 (12.5)  | 0.362     |
| Parkinson's disease/treated essential tremor, n (%) | 9 (3.7)    | 5 (4.4)     | 4 (3.1)    | 0.738     |
| Abuse of alcohol or other drugs, n (%) | 3 (1.2)    | 0            | 3 (2.3)    | 0.250     |
| Others, n (%)                          | 78 (32.5)  | 41 (36.6)   | 37 (28.9)  | 0.204     |

*X2. Statistically significant results are marked in bold.

Table 2  Baseline classification by the Barthel Index and Lawton Scale overall and stratified by sex

| Baseline functional status                          | Total n=241 | Women n=113 | Men n=128 | P values* |
|-----------------------------------------------------|------------|-------------|-----------|-----------|
| Overall functional impairment (Barthel Index <60 or moderate, severe or total dependence based on the Lawton IADL Scale), n (%) | 92 (38.2)  | 50 (44.2)   | 42 (32.8) | 0.068     |
| Barthel Index(BADL), n (%)                          |            |             |           | <0.001    |
| Independent (score: 100)                            | 86 (37.5)  | 24 (21.2)   | 62 (48.4) |           |
| Mildly dependent (score: 60–95)                     | 124 (51.5) | 68 (60.2)   | 56 (43.8) |           |
| Moderately dependent (score: 40–55)                 | 15 (6.2)   | 10 (8.8)    | 5 (3.9)   |           |
| Severely dependent (score: 20–35)                   | 12 (5)     | 9 (8)       | 3 (2.3)   |           |
| Totally dependent (score: <20)                      | 4 (1.7)    | 2 (1.8)     | 2 (1.6)   |           |
| Lawton Scale(IADL), n (%)                           |            |             |           | 0.011     |
| Independent (women 8 points, men 5)                 | 76 (31.5)  | 32 (28.3)   | 44 (34.4) |           |
| Mildly dependent (women 6–7 points, men 4)          | 73 (30.3)  | 31 (27.4)   | 42 (32.8) |           |
| Moderately dependent (women 4–5 points, men 2–3)    | 43 (17.8)  | 16 (14.2)   | 27 (21.1) |           |
| Severely dependent (women 2–3 points, men 1)        | 27 (11.2)  | 18 (15.9)   | 9 (7)     |           |
| Totally dependent (women 0–1 point, men 0)          | 22 (9.1)   | 16 (14.2)   | 6 (4.7)   |           |

*X2. BADL, basic activities of daily living; IADL, instrumental activities of daily living.
A lower category within the Lawton Scale, functional deterioration in IADL per age (OR=1.12, 95% CI 1.03 to 1.21), and with having had at least one hospital admission during follow-up, were significantly associated with age (OR 1.1, 95% CI 1.02 to 1.16) and with having had at least one hospital admission during the follow-up period. Significant associations were found with older age, functional impairment at baseline and with having had at least one hospital admission during the follow-up period.

Table 3 summarises the results of the logistical regression, assessing the association between functional decline and the independent variables considered, the model explaining between 12.6% and 19.8% of the variance in the dependent variable. Functional decline was found to be significantly associated with age (OR 1.1, 95% CI 1.03 to 1.21) and with having had at least one hospital admission during the 8-month follow-up (OR 3.5, 95% CI 1.6 to 7.7). Regarding only deterioration in BADL performance (being classified in a lower category within the Barthel Index), functional decline was associated with age (OR=1.12, 95% CI 1.03 to 1.21, p=0.005) and with having had at least one admission during the follow-up (OR=3.41, 95% CI 1.37 to 8.48, p=0.008). Regarding deterioration in IADL performance (being classified in a lower category within the Lawton Scale), functional decline was only associated with having had at least one admission during the follow-up period (OR=3.44, 95% CI 1.49 to 7.94, p=0.004).

Table 5 lists the C statistics indicating the ability of baseline characteristics regarded in the model and with having at least one hospital admission during follow-up, together and separately, to discriminate between patients who did and did not have functional decline at 8 months of follow-up. The set of variables together provides good discrimination (C statistics 0.76, 95% CI 0.69 to 0.84), age being the variable with the best discriminatory ability (0.67, 95% CI 0.58 to 0.77).

Regarding the entire follow-up for all the patients initially included (even if they did not complete the 8-month follow-up), there were a total of 133 hospital admissions in 83 patients (34.4%, 95% CI 0.29% to 0.41%); this represents a hospitalisation rate of 0.9 admissions per patient per year considering the cumulative follow-up for all patients. The main causes of the admissions were: respiratory (n=56, of which 51 were due to infection or exacerbation), cardiovascular (28, of which 22 were due to heart failure), neurological (14) and digestive (10); significant association was found between having had an admission related to the first three causes and functional decline at 8 months (p=0.034, 0.006 and 0.012).

### Table 3

Association between functional decline at 8 months with baseline characteristics and with having at least one hospital admission during follow-up

| Baseline characteristics                          | Total (n=200) | Functional decline at 8 months (n=41) | No functional decline at 8 months (n=159) | P values* |
|---------------------------------------------------|---------------|--------------------------------------|------------------------------------------|-----------|
| Age at the start of the study, median (IQR)       | 81 (75–86)    | 85 (80–89)                           | 81 (74–85)                               | 0.001     |
| Sex: women, n (%)                                 | 95 (47.5)     | 24 (58.5)                            | 71 (44.7)                                | 0.112     |
| Number of conditions at baseline, median (IQR)    | 5 (4–6)       | 6 (4.5–7)                            | 5 (4–6)                                  | 0.17      |
| Charlson Index, median (IQR)                      | 3 (2–4)       | 3 (3–4.5)                            | 3 (2–4)                                  | 0.119     |
| Number of regular medications at baseline, median (IQR) | 11 (9–14) | 11 (9–14)                           | 11 (9–14)                               | 0.243     |
| At least one admission during follow-up, n (%)    | 61 (30.5)     | 21 (51.2)                            | 40 (25.2)                                | 0.001     |
| Functional impairment at baseline (scored <60 on the Barthel Index or moderate, severe or total functional impairment based on the Lawton Scale), n (%) | 66 (33.0) | 21 (51.2)                           | 45 (28.3)                               | 0.005     |

*χ² tests for qualitative variables (%) and Mann-Whitney U tests for quantitative variables (age, number of conditions, number of medications). Statistically significant results are marked in bold.

### Table 4

Logistical regression results regarding the association of functional decline at 8 months with baseline characteristics and with having at least one hospital admission during follow-up

| Variable                                | B    | SE   | df | P values | OR (Exp B) | 95% CI       |
|-----------------------------------------|------|------|----|----------|------------|--------------|
| Age                                     | 0.09 | 0.03 | 1  | 0.012    | 1.09       | 1.02 to 1.16 |
| Sex (men vs women)                      | -0.13| 0.42 | 1  | 0.754    | 0.88       | 0.99 to 1.99 |
| Number of comorbid conditions at baseline | 0.04 | 0.17 | 1  | 0.809    | 1.04       | 0.74 to 1.47 |
| Charlson Index                          | 0.12 | 0.14 | 1  | 0.376    | 1.13       | 0.86 to 1.48 |
| Number of regular medications at baseline | 0.01 | 0.06 | 1  | 0.838    | 1.01       | 0.90 to 1.14 |
| Functional impairment at baseline       | 0.57 | 0.41 | 1  | 0.164    | 1.77       | 0.79 to 3.99 |
| At least one hospital admission during the follow-up period | 1.26 | 0.40 | 1  | 0.002    | 3.51       | 1.60 to 7.69 |
between death and having an impaired functional status. There was a significant association functional status at baseline, 10 (40%) with regard to did not improve with the subsequent admission).

status at that point had been poorer than at baseline (and discharge from the previous admission if the functional two evaluation scales), compared with baseline or with assessed on discharge, there was functional decline in 27 cases (35.5%, 95% CI 25.7% to 46.7%) (the patient being assessed on discharge, BADL performance had also assessed. Regarding the 76 admissions for which BADL or both BADL and IADL performance had been assessed on discharge, there was functional decline in 27 cases (35.5%, 95% CI 25.7% to 46.7%) (the patient being classified in a lower category within at least one of the two evaluation scales), compared with baseline or with discharge from the previous admission if the functional status at that point had been poorer than at baseline (and did not improve with the subsequent admission).

Out of the 25 patients who died, 18 (72%) had impaired functional status at baseline, 10 (40%) with regard to BADL performance. There was a significant association between death and having an impaired functional status at baseline (p<0.001).

**DISCUSSION**

Key features of this study that make it important are that it considers patients included in a clinical care programme for patients with multimorbidity, and therefore, who have specific and distinct characteristics to patients just identified as having comorbid conditions, and also that it involves direct assessment of the patients (rather than using only clinical records). Another important feature is that it is one of the few studies carried out in this type of patient in a primary care setting, focusing on functional status as the main outcome variable.18

In investigating all patients with comorbidities is not the same as focusing on patients with comorbidities who, given their characteristics and higher risk or greater complexity, are candidates for inclusion in specific care programmes, called ‘patients with multimorbidity’ or sometimes ‘complex patients’, reflecting a higher level of progression and with clinical implications.19 20

The characteristics of patients with multimorbidity, influenced by inclusion criteria, included: advanced age (median 80 years old, similar to other studies11–13), with a high rate of the selected comorbid conditions (median of 5), similar to some studies18 although higher than in others3,5,10,21; taking multiple medications (median of 11 regular medications), higher than in some studies18; although similar to that found in another study16; and frequently hospitalised (0.9 admissions per person per year of follow-up), as well as often having an impaired functional status (38.2%). In additional analysis conducted (though not described in detail in this paper) comparing patients by method of inclusion in the programme, we only found differences in the number of previous admissions; this seems logical given that the stratification method is based on data from several years prior to the study while newly included patients had to have at least one hospital admission in the year prior to follow-up.

A relatively high percentage of patients (38%) already had an impaired functional status at the start of the study, many (13%) being moderately or totally dependent in BADL or both BADL and IADL performance had been assessed on discharge, BADL performance had also assessed. Regarding the 76 admissions for which BADL or both BADL and IADL performance had been assessed on discharge, there was functional decline in 27 cases (35.5%, 95% CI 25.7% to 46.7%) (the patient being classified in a lower category within at least one of the two evaluation scales), compared with baseline or with discharge from the previous admission if the functional status at that point had been poorer than at baseline (and did not improve with the subsequent admission).

Out of the 25 patients who died, 18 (72%) had impaired functional status at baseline, 10 (40%) with regard to BADL performance. There was a significant association between death and having an impaired functional status at baseline (p<0.001).

**Table 5** Ability of baseline characteristics and with having at least one hospital admission during follow-up, together and separately, to discriminate (C statistics) between patients who did and did not have functional decline at 8 months of follow-up

| Variable                                      | C statistics | 95% CI |
|-----------------------------------------------|--------------|--------|
| All seven variables combined                   | 0.76         | 0.69 to 0.84 |
| Age                                           | 0.67         | 0.58 to 0.77 |
| Sex (men vs women)                            | 0.57         | 0.47 to 0.69 |
| Number of conditions at baseline              | 0.62         | 0.51 to 0.72 |
| Charlson Index                                | 0.58         | 0.47 to 0.68 |
| Number of regular medications at baseline     | 0.56         | 0.46 to 0.66 |
| Functional impairment at baseline             | 0.61         | 0.51 to 0.71 |
| At least one hospital admission during the follow-up period | 0.63 | 0.53 to 0.73 |

0.014, respectively), although not for the admission of digestive cause (p=0.33).

Around two-thirds (64.7%) of admissions were to the main referral hospital and slightly less than a third (29.3%) to the subacute hospital, with a few admissions (6%) to other hospitals. Regarding the 125 (out of the 133) hospital admissions in which the patient did not die, BADL performance was assessed on discharge or within 5 days in 76 cases (60.8%), IADL performance in 67 cases (53.6%) and one of the two in 76 cases (60.8%); that is, in all cases when IADL performance had been assessed on discharge, BADL performance had also been assessed. Regarding the 76 admissions for which BADL or both BADL and IADL performance had been assessed on discharge, there was functional decline in 27 cases (35.5%, 95% CI 25.7% to 46.7%) (the patient being classified in a lower category within at least one of the two evaluation scales), compared with baseline or with discharge from the previous admission if the functional status at that point had been poorer than at baseline (and did not improve with the subsequent admission).

Out of the 25 patients who died, 18 (72%) had impaired functional status at baseline, 10 (40%) with regard to BADL performance. There was a significant association between death and having an impaired functional status at baseline (p<0.001).
In 35.5% of patients with functionality assessed at hospital discharge, functional decline was detected; despite this, in our sample, performance of the ADL was only assessed on discharge with at least one of the specific evaluation scales in 60.8% of the patients admitted to hospital. Our findings underline the importance of assessing functional status in patients with multimorbidity during and after hospitalisation (this being frequent, with a rate of 0.9 admissions per patient per year) and also that this type of assessment is an area for improvement in our setting. Regarding the correct management and intervention of hospital admissions, it is important to highlight that the majority of hospitalisations were caused by expected and limited causes, predominantly respiratory infections or exacerbations and heart failure.

Although several studies have reported an association between functional decline over time with the number and severity of concomitant diseases, 8 21 or with underlying diseases such as heart failure,27 other authors18 indicate poor discrimination between comorbidity or multiple medications and the outcome of functional decline. In this study, only the association of functional decline with the number of chronic diseases/conditions and Charlson Index has been analysed, however not with specific conditions as done in other studies,24 due to a limited sample for each of them.

We should recognise some of the limitations of our study. The inclusion of only three health centres may limit the generalisation of the results, although analysis (not reported) comparing the characteristics of the populations of these centres with those of all the other health centres in the same health district did not find significant differences in terms of demographic or socioeconomic characteristics. Additionally, although we are currently working on data for a longer period of follow-up with this sample of patients, in this paper we report on a follow-up of just 8 months, which could be considered a relatively short period of time for analysing the main outcome variables; nevertheless, having found higher levels of variation than in other studies with longer follow-ups, we consider it interesting to analyse the changes observed, as the identification of a decline over a short period implies that the decline is being detected promptly, enabling early interventions that might be more effective than interventions used when decline is more established.

The fact that direct assessment of ADL like performance tests was not used, and that so much ADL data on discharge were lacking for patients is a limiting factor. On the other hand, it could have been interesting to have expected and limited causes, predominantly respiratory infections or exacerbations and heart failure.

In line with other authors,28 we consider it important to carry out more research between the association of the multimorbidity and the functional status and its deterioration, and to specify the subgroups of patients in whom this association is more intense; to discriminate between which factors are more related to this functional decline and its intervention, and highlighting the importance on the primary care setting, with the goal of improving interventions for this population.

Author affiliations
1San Ignacio Health Centre, Bilbao-Basurto Integrated Healthcare Organisation (IHO), Basque Health Service (Osakidetza), Bilbao, Spain
2Bizkaia Unit for Multiprofessional Training in Family and Community Care, Basque Health Service, Bilbao, Spain
3Bilbao-Basurto IHO, Osakidetza, Bilbao, Spain
4Emergency Department, Urduliz Hospital, Osakidetza, Urduliz, Spain
5Emergency Department, Basurto University Hospital, Bilbao-Basurto IHO, Osakidetza, Bilbao, Spain
6Internal Medicine Department, Santa Marina Hospital, Osakidetza, Bilbao, Spain
7Internal Medicine Department, Basurto University Hospital, Bilbao-Basurto IHO, Osakidetza, Bilbao, Spain

Acknowledgements We thank the professionals from San Ignacio, Deusto and Gazteleku Primary Health Care Centres and those from the Basurto and Santa Marina Hospitals who have collaborated with us along the study, as well as the patients themselves, and their families for their generous contribution.

Contributors All authors have been involved from the beginning in all phases of the study with varying intensity according to the study’s successive needs. IML, as the principal investigator (PI), participated in all aspects of the project, coordinating the different stages of the study too. IML and LIMC have had a transcendental role in the methodological and analytical aspects. SCM, ASDO, IGB, JPR and INP have made the clinical assessments of most patients and managed their clinical data. ISA and MURF made the clinical assessments of most patients at hospital discharge. All authors have read and approved the final version of this manuscript.

Funding This work was supported by a Bilbao-Basurto IHO grant (OSIBB17/002).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Clinical Research Ethics Committee of Euskadi (P2016082, 24 June 2016).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Being the first article of the FUNCIPLUR study, there are no additional data available directly by now. However, we are willing to complete or give more information or data to other authors who require it.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. Whitson HE, Boyd CM. Managing multiple comorbidities. In: Uptodate 2017. https://www.uptodate.com/contents/managing-multiple-comorbidities (accessed 5 Apr 2018).
2. Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. BMJ 2015;350:h176.
3. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014;9:e102149.
4. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: A systematic review of the literature. Ageing Res Rev 2011;10:430–9.
5. Boeckxstaens P, Vaes B, Legrand D, et al. The relationship of multimorbidity with disability and frailty in the oldest patients: a cross-sectional analysis of three measures of multimorbidity in the BELFRAIL cohort. Eur J Gen Pract 2015;21:39–44.
6. Huntley AL, Johnson R, Purdy S, et al. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann Fam Med 2012;10:134–41. (accessed 29 Jul 2018).
7. Spanish Ministry of Health and Social Policy. Unit for Highly Complex Patients with Multiple Chronic Conditions Standards and Recommendations. 2009 http://www.msc.es/organizacion/sns/planCalidadSNS/docs/pluripatologicos_en.pdf (accessed 5 Apr 2018).

8. Ryan A, Wallace E, O’Hara P, et al. Multimorbidity and functional decline in community-dwelling adults: a systematic review. *Health Qual Life Outcomes* 2015;13:168.

9. Smith SM, Soubhi H, Fortin M, et al. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. *Cochrane Database Syst Rev* 2012;4:CD006560.

10. Marengoni A, von Strauss E, Rizzato D, et al. The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. *J Intern Med* 2009;265:288–95.

11. Hoogerdijin JG, Buurman BM, Korevaar JC, et al. The prediction of functional decline in older hospitalised patients. *Age Ageing* 2012;41:381–7.

12. Helvik AS, Selbaek G, Engeda K. Functional decline in older adults one year after hospitalization. *Arch Gerontol Geriatr* 2013;57:305–10.

13. Boyd CM, Landefeld CS, Counsell SR, et al. Recovery of Activities of Daily Living in Older Adults After Hospitalization for Acute Medical Illness. *J Am Geriatr Soc* 2008;56:2171–9.

14. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J* 1965;14:61–5.

15. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* 1969;9:179–86.

16. Martin-Lesende I, Maroto MC, Peña ML, et al. Frailty and Related Factors Based On A Multidimensional Assessment In People 70 Years Old Or Over. *MOJ Gerontol Ger* 2017;1:00004.

17. Swets J. Measuring the accuracy of diagnostic systems. *Science* 1988;240:1285–93.

18. Wallace E, McDowell F, Bennett K, et al. Comparison of count-based multimorbidity measures in predicting emergency admission and functional decline in older community-dwelling adults: a prospective cohort study. *BMJ Open* 2016;6:e013089.

19. NICE guideline. Multimorbidity: clinical assessment and management. 2016 www.nice.org.uk/guidance/ng56 (accessed 29 Jun 2018).

20. Marventano S, Ayala A, Gonzalez N, et al. Multimorbidity and functional status in community-dwelling older adults. *Eur J Intern Med* 2014;25:610–6.

21. Wang XX, Lin WQ, Chen XJ, et al. Multimorbidity associated with functional independence among community-dwelling older people: a cross-sectional study in Southern China. *Health Qual Life Outcomes* 2017;15:73.

22. Kadum UT, Croft PR. North Staffordshire GP Consortium Group. Clinical multimorbidity and physical function in older adults: a record and health status linkage study in general practice. *Fam Pract* 2007;24:412–9.

23. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev* 2011;10:430–9.

24. Martin-Lesende I, Iturbe AG, Molina M, et al. Frail elderly people: Detection and management in primary care. *Eur Geriatr Med* 2015;6:447–55.

25. Garvey J, Connolly D, Boland F, et al. OPTIMAL, an occupational therapy led self-management support programme for people with multimorbidity in primary care: a randomized controlled trial. *BMJ Fam Pract* 2015;16:59.

26. Rodríguez-Mañas L, Marchán E, Conde C, et al. Deterioro de la capacidad funcional en pacientes ancianos ingresados en un servicio de medicina interna. *An Med Interna* 2005;22:130–2.

27. Di Bari M, Virgillo A, Matteuzzi D, et al. Predictive validity of measures of comorbidity in older community dwellers: the Insufficienza Cardiaca negli Anziani Residenti a Dicomano Study. *J Am Geriatr Soc* 2006;54:210–6.

28. Smith SM, Bayliss EA, Mercer SW, et al. How to design and evaluate interventions to improve outcomes for patients with multimorbidity. *J Comorb* 2013;3:10–17.